Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib

NCT05423691 is registered in ClinicalTrials.gov with Cellenkos, Inc. as lead sponsor.

NCT NCT05423691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05423691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib
Lead sponsor
Cellenkos, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 27, 2022
Completion date
December 30, 2026
Enrollment
24 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis